November 2, 2018 / 11:29 AM / 13 days ago

CORRECTED-BRIEF-Epizyme Reports Q3 Loss of $0.54 Per Share

(Corrects headline to say loss, not earnings)

Nov 2 (Reuters) - Epizyme Inc:

* EPIZYME REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND TAZEMETOSTAT PROGRESS

* Q3 LOSS PER SHARE $0.54

* Q3 EARNINGS PER SHARE VIEW $-0.61 — THOMSON REUTERS I/B/E/S

* RESEARCH AND DEVELOPMENT EXPENSES WERE $27.0 MILLION FOR Q3 OF 2018, WHICH COMPARES TO $28.7 MILLION FOR Q3 OF 2017

* EXPECTS EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND ITS PLANNED OPERATIONS INTO Q1 OF 2020

* ENROLLMENT IN PHASE 2 COHORT OF FOLLICULAR LYMPHOMA PATIENTS WITH EZH2 ACTIVATING MUTATIONS ON TRACK TO BE COMPLETED BY YEAR END

* RECENT FINANCING EXTENDS OPERATING RUNWAY INTO Q1 OF 2020

* EPIZYME - UPDATED EFFICACY & SAFETY DATA FOR TAZEMETOSTAT IN EPITHELIOID SARCOMA SUPPORT CO’S PLANNED SUBMISSION OF NEW DRUG APPLICATION IN H1 OF 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below